Recognizing and managing on toxicities in cancer immunotherapy
Over the past 4 years, cancer immunotherapy has significantly prolonged survival time of patients with prostate cancer, melanoma, lung cancer, and liver cancer, but its side effects are also impressive. Different types of the immune therapeutic agents have different on-target or off-target toxicity...
Saved in:
Main Authors: | Liu Yang, Huifang Yu, Shuang Dong, Yi Zhong, Sheng Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-03-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317694542 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?
by: Shuang Wei, et al.
Published: (2025-07-01) -
From Building Corpora for Recognizing Faceted Entailment to Recognizing Relational Entailment
by: Martin Víta
Published: (2018-09-01) -
Immunotherapy for Pancreatic Cancer
by: Koido, Shigeo, et al.
Published: (2012) -
Targeted Apoptosis in Breast Cancer Immunotherapy
by: Jia, Lin-Tao, et al.
Published: (2012) -
Circulating Plasma Proteins as Biomarkers for Immunotherapy Toxicity: Insights from Proteome-Wide Mendelian Randomization and Bioinformatics Analysis
by: Liansha Tang, et al.
Published: (2025-07-01)